

ASX ANNOUNCEMENT**19 January 2023****Cann Group Announces Preliminary Results from their
Phase 3 clinical trial**

- Trial compared the efficacy of low dose Satipharm® CBD capsules to placebo in treating sleep disturbances.
 - Three doses of Satipharm® CBD capsules were compared to placebo in a randomised, double-blind, placebo-controlled, multicentre clinical trial that included a total of 257 participants with sleep disturbances.
 - Preliminary view of the analysis of the primary end-points have not shown a statistically superior response compared to placebo.
 - Cann Group expects these trial results will delay submission of the registration application to the Therapeutic Goods Administration (TGA) for this indication.
 - Once the full data set (including the secondary end-points) and report of the clinical trial is delivered to the company, Cann Group will evaluate the data and review its approach for this indication. A market update will be published once that review is complete.
-

Authorised for release by the Board of Directors of Cann Group Limited.

For all information please contact:

Peter Koetsier
CEO
Cann Group Limited
+61 3 9095 7088
contact@canngrouponlimited.com

Deborah Ambrosini
CFO & Company Secretary
Cann Group Limited
+61 3 9095 7088
deborah.ambrosini@canngrouponlimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is enhancing patients' lives by developing, producing, and supplying innovative cannabis medicines. The Company has built world-class research, cultivation and GMP manufacturing facilities in Melbourne, and a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

Learn more at: www.canngrouponlimited.com | www.satipharm.com